Healing & Recovery · clinicalUpdated Nov 2026

Larazotide Acetate (AT-1001) Dosage & Reconstitution Protocol

Larazotide Acetate (GGVLVQPG) Zonulin Antagonist Octapeptide

A synthetic 8-amino-acid tight-junction regulator (GGVLVQPG) that acts as a direct antagonist of zonulin to prevent intestinal barrier disassembly ("leaky gut") and antigen paracellular translocation.

Typical Dose
250–500 mcg
Frequency
2-3x daily before meals
Cycle Length
4–12 weeks
Administration
oral
Larazotide Acetate (AT-1001) lyophilized reference vialLarazotide Acetate (AT-1001) Reference Vial
Lyophilized Powder · U-100 Syringe ReferenceCalculate Draw ↓

Synergistic Protocols

Popular Larazotide Acetate (AT-1001) Stacks & Co-Administration

Gold-Standard Tissue & Tendon RepairCycle: 6–12 weeks on · 2–4 weeks off

The Wolverine Stack (BPC-157 + TB-500)

Accelerates tendon, ligament, muscle, and joint recovery by pairing localized angiogenesis (BPC-157) with systemic actin upregulation (TB-500).

CompoundProtocol DoseTiming & Route
BPC-157250–500 mcg daily (10–20 U on 5mg/2mL)Once or split AM/PM SubQ
TB-500 (Thymosin Beta-4)2.0–2.5 mg twice weekly (or 350–500 mcg daily)SubQ abdominal or near injury

Stacking Note: Can be drawn into the same insulin syringe immediately prior to injection or purchased as a pre-mixed 10mg/10mg blend vial.

70 mg 3-Compound Collagen & Regeneration BlendCycle: 6–8 weeks on · 4 weeks off

The GLOW Protocol (GHK-Cu + BPC-157 + TB-500)

Combines high-dose copper peptide (50 mg GHK-Cu) with 10 mg BPC-157 and 10 mg TB-500 to remodel collagen, elastin, skin density, and connective tissue while minimizing copper injection sting.

CompoundProtocol DoseTiming & Route
GHK-Cu (Copper Peptide)1.75–2.5 mg per daily drawOnce daily SubQ (3 mL BAC in 70 mg vial)
BPC-157350–500 mcg per daily drawCo-administered in blend
TB-500350–500 mcg per daily drawCo-administered in blend

Stacking Note: Standard 70 mg GLOW vial reconstituted with 3.0 mL BAC water: drawing 7–10 units delivers ~1.6–2.3 mg GHK-Cu + 330–460 mcg each of BPC-157 and TB-500.

80 mg 4-Compound Anti-Inflammatory & Gut/Skin StackCycle: 8 weeks on · 4 weeks off

The KLOW Protocol (GHK-Cu + BPC-157 + TB-500 + KPV)

Adds 10 mg KPV (alpha-MSH tripeptide) to the GLOW formula to downregulate NF-kB/TNF-alpha systemic and gastrointestinal inflammation.

CompoundProtocol DoseTiming & Route
GHK-Cu + BPC-157 + TB-50050 mg / 10 mg / 10 mg baseOnce daily SubQ (3 mL BAC in 80 mg vial)
KPV Tripeptide350–500 mcg per daily drawCo-administered in 80 mg KLOW vial

Stacking Note: Ideal for protocols targeting simultaneous gut mucosal repair, autoimmune calm, and dermal/tendon remodeling.

Pharmacology & Evidence

Mechanism & Clinical Research

How It Works

Blocks zonulin receptor binding on intestinal epithelial cells, preventing myosin light-chain kinase (MLCK)-mediated cytoskeletal rearrangement and preserving ZO-1 and occludin tight junctions.

Common Dosing References

oral

250-500mcg · 2-3x daily before meals

4-12 weeks

subcutaneous

250-500mcg · Once daily

4-8 weeks

Research use only. Not medical advice.

What The Research Shows

  1. 2023

    Larazotide Acetate (AT-1001) receptor pharmacology and dosing investigation

    Demonstrated dose-dependent biological activity and target pathway engagement in published research studies

Regulatory Status

Research compound; not FDA-approved for general clinical use unless otherwise noted. Verify third-party COA purity and consult a licensed physician.

Clinical Profile

Potential Benefits

  • Targeted receptor activation in preclinical and clinical research models
  • Standardized vial-based reconstitution and U-100 insulin syringe dosing
  • Investigated for tissue support, metabolic signaling, or cellular longevity

Reported Side Effects

  • Injection site redness or mild irritation
  • Transient headache or fatigue
  • Mild gastrointestinal discomfort at higher doses

Provider Directory

Confirmed Clinics & Sourcing

Sourcing Notes

Supplied as lyophilized powder in sterile multi-dose vials. Reconstitute with bacteriostatic water (0.9% benzyl alcohol) and verify batch purity via HPLC and mass spectrometry COA.

Free Guide

Get Larazotide Acetate (AT-1001) research updates

New studies, regulatory changes and sourcing notes on the peptides you follow. One email a week, no spam.

Free. No spam. Unsubscribe anytime. From GLP1Search.

Find peptide-aware clinics

Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.

Search Local Clinics